Advanced search
Publication Cover
Epigenomics Volume 7, 2015 - Issue 5
Submit an article Journal homepage
219
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Epigenetic Reprogramming in Solid Tumors: Therapeutic Implications of EZH2 Gain-Of-Function Mutations

Anthony M Barsotti1 Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY10965, USA;2 Kadmon Pharmaceuticals, New York, NY10016, USAView further author information
,
Michael Ryskin1 Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY10965, USAView further author information
&
Robert A Rollins1 Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY10965, USACorrespondence[email protected]
View further author information
Pages 687-690 | Published online: 28 Aug 2015

References

  • Kandoth C , McLellanMD , VandinFet al. Mutational landscape and significance across 12 major cancer types . Nature502 ( 7471 ), 333 – 339 ( 2013 ).
  • Helin K , DhanakD . Chromatin proteins and modifications as drug targets . Nature502 ( 7472 ), 480 – 488 ( 2013 ).
  • Suva ML , RiggiN , BernsteinBE . Epigenetic reprogramming in cancer . Science339 ( 6127 ), 1567 – 1570 ( 2013 ).
  • Bracken AP , HelinK . Polycomb group proteins: navigators of lineage pathways led astray in cancer . Nat. Rev. Cancer9 ( 11 ), 773 – 784 ( 2009 ).
  • Sparmann A , Van LohuizenM . Polycomb silencers control cell fate, development and cancer . Nat. Rev. Cancer6 ( 11 ), 846 – 856 ( 2006 ).
  • McCabe MT , CreasyCL . EZH2 as a potential target in cancer therapy . Epigenomics6 ( 3 ), 341 – 351 ( 2014 ).
  • Bachmann IM , HalvorsenOJ , CollettKet al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast . J. Clin. Oncol.24 ( 2 ), 268 – 273 ( 2006 ).
  • Morin RD , JohnsonNA , SeversonTMet al. Somatic mutations altering EZH2 (tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin . Nat. Genet.42 ( 2 ), 181 – 185 ( 2010 ).
  • Bodor C , GrossmannV , PopovNet al. EZH2 mutations are frequent and represent an early event in follicular lymphoma . Blood122 ( 18 ), 3165 – 3168 ( 2013 ).
  • Ott HM , GravesAP , PappalardiMBet al. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation . Mol. Cancer Ther.13 ( 12 ), 3062 – 3073 ( 2014 ).
  • Hodis E , WatsonIR , KryukovGVet al. A landscape of driver mutations in melanoma . Cell150 ( 2 ), 251 – 263 ( 2012 ).
  • Krauthammer M , KongY , HaBHet al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma . Nat. Genet.44 ( 9 ), 1006 – 1014 ( 2012 ).
  • Sneeringer CJ , ScottMP , KuntzKWet al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas . Proc. Natl Acad. Sci. USA107 ( 49 ), 20980 – 20985 ( 2010 ).
  • McCabe MT , OttHM , GanjiGet al. EZH2 inhibition as a therapeutic strategy for lymphoma with ezh2-activating mutations . Nature492 ( 7427 ), 108 – 112 ( 2012 ).
  • Knutson SK , KawanoS , MinoshimaYet al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-hodgkin lymphoma . Mol. Cancer Ther.13 ( 4 ), 842 – 854 ( 2014 ).
  • Beguelin W , PopovicR , TeaterMet al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation . Cancer Cell23 ( 5 ), 677 – 692 ( 2013 ).
  • Barsotti AM , RyskinM , ZhongWet al. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth . Oncotarget6 ( 5 ), 2928 – 2938 ( 2015 ).
  • Zingg D , DebbacheJ , SchaeferSMet al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors . Nat. Commun.6 , 6051 ( 2015 ).
  • Shen C , VakocCR . Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention . Curr. Opin. Oncol.27 ( 1 ), 57 – 63 ( 2015 ).
  • Tiffen J , GallagherSJ , HerseyP . EZH2: An emerging role in melanomabiology and strategi es for targeted therapy . Pigment Cell Melanoma Res.28 ( 1 ), 21 – 30 ( 2015 ).
  • McHugh JB , FullenDR , MaL , KleerCG , SuLD . Expression of polycombgroup protein EZH2 in nevi and melanoma . J. Cutan. Pathol.34 ( 8 ), 597 – 600 ( 2007 ).
  • Ahuja N , EaswaranH , BaylinSB . Harnessing the potential of epigenetic therapy to targetsolid tumors . J. Clin. Invest.124 ( 1 ), 56 – 63 ( 2014 ).
  • Azad N , ZahnowCA , RudinCM , BaylinSB . The future of epigenetic therapyin solid tumours – lessons from the past . Nat. Rev. Clin. Oncol.10 ( 5 ), 256 – 266 ( 2013 ).
  • Dupage M , ChopraG , QuirosJet al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation . Immunity42 ( 2 ), 227 – 238 ( 2015 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.